FI3823990T3 - Cd19:ään sitoutuvia raskasketjun vasta-aineita - Google Patents
Cd19:ään sitoutuvia raskasketjun vasta-aineitaInfo
- Publication number
- FI3823990T3 FI3823990T3 FIEP19749123.6T FI19749123T FI3823990T3 FI 3823990 T3 FI3823990 T3 FI 3823990T3 FI 19749123 T FI19749123 T FI 19749123T FI 3823990 T3 FI3823990 T3 FI 3823990T3
- Authority
- FI
- Finland
- Prior art keywords
- heavy chain
- antibody
- multispecific
- seq
- multispecific antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862701281P | 2018-07-20 | 2018-07-20 | |
| PCT/US2019/042633 WO2020018922A1 (en) | 2018-07-20 | 2019-07-19 | Heavy chain antibodies binding to cd19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3823990T3 true FI3823990T3 (fi) | 2026-03-16 |
Family
ID=67515196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP19749123.6T FI3823990T3 (fi) | 2018-07-20 | 2019-07-19 | Cd19:ään sitoutuvia raskasketjun vasta-aineita |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US12202898B2 (enExample) |
| EP (2) | EP3823990B1 (enExample) |
| JP (2) | JP7439046B2 (enExample) |
| KR (2) | KR20260036383A (enExample) |
| CN (2) | CN116769032A (enExample) |
| AU (2) | AU2019305663B2 (enExample) |
| BR (1) | BR112020024074A2 (enExample) |
| CA (1) | CA3101069A1 (enExample) |
| DK (1) | DK3823990T3 (enExample) |
| ES (1) | ES3064933T3 (enExample) |
| FI (1) | FI3823990T3 (enExample) |
| HR (1) | HRP20260372T1 (enExample) |
| IL (2) | IL326259A (enExample) |
| LT (1) | LT3823990T (enExample) |
| MX (1) | MX2021000708A (enExample) |
| PL (1) | PL3823990T3 (enExample) |
| PT (1) | PT3823990T (enExample) |
| RS (1) | RS67881B1 (enExample) |
| SG (1) | SG11202011597RA (enExample) |
| SI (1) | SI3823990T1 (enExample) |
| SM (1) | SMT202600121T1 (enExample) |
| WO (1) | WO2020018922A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL299221A (en) | 2016-06-21 | 2023-02-01 | Teneobio Inc | Cd3 binding antibodies |
| CN109862784A (zh) | 2016-08-24 | 2019-06-07 | 特尼奥生物股份有限公司 | 产生经修饰的仅有重链的抗体的转基因非人动物 |
| CR20220578A (es) | 2016-09-14 | 2023-01-17 | Teneobio Inc | Anticuerpos de unión a cd3 |
| EP3559035A1 (en) | 2016-12-21 | 2019-10-30 | TeneoBio, Inc. | Anti-bcma heavy chain-only antibodies |
| CN110891971B (zh) | 2017-06-20 | 2024-01-12 | 特尼奥生物股份有限公司 | 仅有重链的抗bcma抗体 |
| JP7240335B2 (ja) | 2017-06-20 | 2023-03-15 | テネオワン， インコーポレイテッド | 抗ｂｃｍａ重鎖のみ抗体 |
| EA202091557A1 (ru) | 2017-12-22 | 2020-11-18 | Тенеобио, Инк. | Антитела, содержащие только тяжелые цепи, которые связываются с cd22 |
| LT3823990T (lt) | 2018-07-20 | 2026-04-10 | TeneoTwo, Inc. | Antikūnai iš sunkiosios grandinės, besirišantys prie cd19 |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| CA3133654A1 (en) | 2019-04-05 | 2020-10-08 | Teneobio, Inc. | Heavy chain antibodies binding to psma |
| CN114206927B (zh) | 2019-06-14 | 2025-03-21 | 特尼奥生物股份有限公司 | 与cd22和cd3结合的多特异性重链抗体 |
| WO2021188599A1 (en) * | 2020-03-16 | 2021-09-23 | University Of Southern California | Novel antigen binding domains and synthetic antigen receptors incorporating the same |
| UA130700C2 (uk) * | 2020-04-29 | 2026-04-22 | Тенеобіо, Інк. | Поліспецифічні антитіла, що містять тільки важкі ланцюги, з модифікованими константними областями важкого ланцюга |
| KR20250007022A (ko) | 2020-04-29 | 2025-01-13 | 테네오원, 인코포레이티드 | 변형된 중쇄 불변 영역을 갖는 다중특이적 중쇄 항체 |
| CA3186065A1 (en) * | 2020-07-16 | 2022-01-20 | Xiaohu FAN | Cd19 binding molecules and uses thereof |
| JP7846667B2 (ja) | 2020-07-16 | 2026-04-15 | レジェンド バイオテック アイルランド リミテッド | Ｃｄ２０結合分子及びその使用 |
| AU2021345124A1 (en) | 2020-09-16 | 2023-03-30 | Amgen Inc. | Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer |
| MX2023009882A (es) * | 2021-02-26 | 2023-08-30 | Teneobio Inc | Anticuerpos anti-muc1-c y estructuras car-t. |
| PE20260568A1 (es) * | 2021-04-06 | 2026-03-10 | Teneobio Inc | Anticuerpos anti-cd19 y estructuras car-t |
| WO2024243093A2 (en) * | 2023-05-19 | 2024-11-28 | The Regents Of The University Of California | Multispecific antibodies targeting cd3 and cd22 |
| EP4566619A1 (en) * | 2023-12-08 | 2025-06-11 | AvenCell Therapeutics Inc. | Targeting modules against cd19 and cd20 for use in a method for stimulating a reversed chimeric antigen receptor-mediated immune response in a mammal |
| TW202608445A (zh) * | 2024-04-19 | 2026-03-01 | 美商泰尼歐圖股份有限公司 | 用於治療ｂ－細胞惡性腫瘤之阿卡替尼（ａｃａｌａｂｒｕｔｉｎｉｂ）及多特異性抗體之治療組合 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US6066721A (en) | 1995-07-06 | 2000-05-23 | Stanford University | Method to produce novel polyketides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| UA74798C2 (uk) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
| AU6232899A (en) | 1999-10-06 | 2001-05-10 | Campina Melkunie B.V. | Use of transforming growth factor beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa |
| AU2002238052A1 (en) | 2001-02-20 | 2002-09-04 | Zymogenetics, Inc. | Antibodies that bind both bcma and taci |
| GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
| MXPA05004677A (es) | 2002-10-31 | 2005-11-17 | Genentech Inc | Metodos y composiciones para aumentar la produccion de anticuerpos. |
| WO2004065417A2 (en) | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| US20060008548A1 (en) | 2003-11-19 | 2006-01-12 | Invista North America S.A R.L. | Spinneret plate for producing a bulked continuous filament having a three-sided exterior cross-section and a convex six-sided central void |
| EP1776383B1 (en) | 2004-07-22 | 2014-08-20 | Erasmus University Medical Center Rotterdam | Binding molecules |
| PT1853718E (pt) * | 2005-02-15 | 2015-11-12 | Univ Duke | Anticorpos anti-cd19 e usos em oncologia |
| CN101218351A (zh) * | 2005-02-15 | 2008-07-09 | 杜克大学 | 抗cd19抗体及其在肿瘤学中的应用 |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| KR101703299B1 (ko) | 2007-06-01 | 2017-02-06 | 오픈 모노클로날 테크놀로지, 인코포레이티드 | 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물 |
| US20100122358A1 (en) | 2008-06-06 | 2010-05-13 | Crescendo Biologics Limited | H-Chain-only antibodies |
| AU2009272771B2 (en) * | 2008-07-17 | 2012-09-20 | Novartis Ag | Compositions and methods of use for therapeutic antibodies |
| CN102421801B (zh) | 2009-03-10 | 2016-03-16 | 比奥根Ma公司 | 抗-bcma抗体 |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| JP6636803B2 (ja) | 2013-02-05 | 2020-01-29 | エンクマフ エスアーエールエル | Ｂｃｍａに対する抗体の選択のための方法 |
| EA201790719A1 (ru) * | 2014-09-26 | 2017-07-31 | Макродженикс, Инк. | Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения |
| CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| US9914683B2 (en) | 2016-05-26 | 2018-03-13 | X Development Llc | Fuel synthesis from an aqueous solution |
| IL299221A (en) | 2016-06-21 | 2023-02-01 | Teneobio Inc | Cd3 binding antibodies |
| CN109862784A (zh) | 2016-08-24 | 2019-06-07 | 特尼奥生物股份有限公司 | 产生经修饰的仅有重链的抗体的转基因非人动物 |
| CR20220578A (es) | 2016-09-14 | 2023-01-17 | Teneobio Inc | Anticuerpos de unión a cd3 |
| EP3559035A1 (en) | 2016-12-21 | 2019-10-30 | TeneoBio, Inc. | Anti-bcma heavy chain-only antibodies |
| CN110891971B (zh) | 2017-06-20 | 2024-01-12 | 特尼奥生物股份有限公司 | 仅有重链的抗bcma抗体 |
| JP7240335B2 (ja) | 2017-06-20 | 2023-03-15 | テネオワン， インコーポレイテッド | 抗ｂｃｍａ重鎖のみ抗体 |
| WO2019006072A1 (en) | 2017-06-30 | 2019-01-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | CHIMERIC ANTIGENIC RECEPTORS TO ANTIGEN OF MATURATION OF LYMPHOCYTES B WITH HUMAN DOMAINS |
| EP3732199A1 (en) | 2017-12-27 | 2020-11-04 | TeneoBio, Inc. | Cd3-delta/epsilon heterodimer specific antibodies |
| BR112020023975A2 (pt) | 2018-05-24 | 2021-02-23 | Ayala Pharmaceuticals Inc. | composições que compreendem os compostos de bisfluoroalquil-1,4-benzodiazepinona e imunoterapêuticos e métodos de uso das mesmas |
| LT3823990T (lt) | 2018-07-20 | 2026-04-10 | TeneoTwo, Inc. | Antikūnai iš sunkiosios grandinės, besirišantys prie cd19 |
| CN114206927B (zh) | 2019-06-14 | 2025-03-21 | 特尼奥生物股份有限公司 | 与cd22和cd3结合的多特异性重链抗体 |
| KR20250007022A (ko) | 2020-04-29 | 2025-01-13 | 테네오원, 인코포레이티드 | 변형된 중쇄 불변 영역을 갖는 다중특이적 중쇄 항체 |
-
2019
- 2019-07-19 LT LTEPPCT/US2019/042633T patent/LT3823990T/lt unknown
- 2019-07-19 FI FIEP19749123.6T patent/FI3823990T3/fi active
- 2019-07-19 SG SG11202011597RA patent/SG11202011597RA/en unknown
- 2019-07-19 HR HRP20260372TT patent/HRP20260372T1/hr unknown
- 2019-07-19 DK DK19749123.6T patent/DK3823990T3/da active
- 2019-07-19 BR BR112020024074-5A patent/BR112020024074A2/pt unknown
- 2019-07-19 EP EP19749123.6A patent/EP3823990B1/en active Active
- 2019-07-19 EP EP25219867.6A patent/EP4714502A2/en active Pending
- 2019-07-19 IL IL326259A patent/IL326259A/en unknown
- 2019-07-19 AU AU2019305663A patent/AU2019305663B2/en active Active
- 2019-07-19 JP JP2021502833A patent/JP7439046B2/ja active Active
- 2019-07-19 PT PT197491236T patent/PT3823990T/pt unknown
- 2019-07-19 SI SI201931034T patent/SI3823990T1/sl unknown
- 2019-07-19 US US17/260,213 patent/US12202898B2/en active Active
- 2019-07-19 CN CN202310539593.8A patent/CN116769032A/zh active Pending
- 2019-07-19 MX MX2021000708A patent/MX2021000708A/es unknown
- 2019-07-19 KR KR1020267005215A patent/KR20260036383A/ko active Pending
- 2019-07-19 ES ES19749123T patent/ES3064933T3/es active Active
- 2019-07-19 CN CN201980035712.8A patent/CN112351997B/zh active Active
- 2019-07-19 CA CA3101069A patent/CA3101069A1/en active Pending
- 2019-07-19 PL PL19749123.6T patent/PL3823990T3/pl unknown
- 2019-07-19 WO PCT/US2019/042633 patent/WO2020018922A1/en not_active Ceased
- 2019-07-19 KR KR1020207034987A patent/KR102930803B1/ko active Active
- 2019-07-19 RS RS20260319A patent/RS67881B1/sr unknown
- 2019-07-19 SM SM20260121T patent/SMT202600121T1/it unknown
-
2020
- 2020-11-26 IL IL279010A patent/IL279010B2/en unknown
-
2024
- 2024-02-14 JP JP2024020312A patent/JP7737488B2/ja active Active
-
2026
- 2026-07-02 AU AU2026205247A patent/AU2026205247A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021527431A5 (enExample) | ||
| JP2023526774A5 (enExample) | ||
| FI3322727T3 (fi) | Humanisoituja tai kimeerisiä CD3-vasta-aineita | |
| FI3826667T3 (fi) | Claudin6 vasta-aineita ja menetelmiä syövän hoitamiseksi | |
| IL299221A (en) | Cd3 binding antibodies | |
| JP2021530236A5 (enExample) | ||
| PH12019502785A1 (en) | Anti trbc1 antigen binding domains | |
| FI3332006T3 (fi) | Uusia anti-PD-L1-vasta-aineita | |
| JP2017535257A5 (enExample) | ||
| MY200988A (en) | CD3 Binding Antibodies | |
| IL265541B1 (en) | Bispecific antibodies and compositions comprising thereof for treating cancer | |
| RU2010100638A (ru) | Композиции и способы лечения, направленные против cd20 | |
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| RU2016124540A (ru) | Композиции, содержащие анти-сеасам 1 и анти-pd антитела для терапии рака | |
| JP2018532383A5 (enExample) | ||
| RU2016129517A (ru) | Биспецифические антитела к her2 и способы применения | |
| JP2018528776A5 (enExample) | ||
| RU2014122990A (ru) | Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas | |
| PE20231080A1 (es) | Anticuerpos que se unen a cd3 y cd19 | |
| IL280487B2 (en) | Anti-mica/b antibodies that block mica/b shedding and methods of use | |
| RU2014153440A (ru) | Антитела против cd26 и их применение | |
| EA201691858A1 (ru) | Композиции антител для лечения опухолей | |
| WO2020257789A3 (en) | Anti-tim-3 antibodies | |
| IL250289B2 (en) | Antibodies against angiopoietin-like 4 and methods of use |